MedPath

SABYASACHI SEN

🇮🇳India
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

3

Active:0
Completed:2

Trial Phases

1 Phases

Phase 4:2

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 4
2 (100.0%)

Impact of Semaglutide on CD34+ EPC and Fat Derived MSC

Phase 4
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Drug: Placebos
First Posted Date
2019-10-15
Last Posted Date
2024-04-26
Lead Sponsor
Sabyasachi Sen
Target Recruit Count
38
Registration Number
NCT04126603
Locations
🇺🇸

The GW Medical Faculty Associates, Washington, District of Columbia, United States

🇺🇸

Washington VA Medical Center, Washington, District of Columbia, United States

Effect on HIV Medications on EPC Cells

First Posted Date
2018-12-20
Last Posted Date
2022-03-22
Lead Sponsor
Sabyasachi Sen
Target Recruit Count
22
Registration Number
NCT03782142
Locations
🇺🇸

The GW Medical Faculty Associates, Washington, District of Columbia, United States

Effect of Saxagliptin and Dapagliflozin on Endothelial Progenitor Cell in Patients With Type 2 Diabetes Mellitus

Phase 4
Terminated
Conditions
Cardiovascular Diseases
Diabetes Mellitus, Type 2
Interventions
First Posted Date
2018-09-06
Last Posted Date
2023-06-05
Lead Sponsor
Sabyasachi Sen
Target Recruit Count
15
Registration Number
NCT03660683
Locations
🇺🇸

The GW Medical Faculty Associates, Washington, District of Columbia, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.